RECENT NEWS

Roche has received the CE Mark for its Elecsys pTau181 test to measure phosphorylated Tau (pTau) 181 protein, which is an indicator of amyloid pathology, a hallmark of Alzheimer’s disease.

US biotechnology firm Spear Bio has announced the commercial launch of its SPEAR UltraDetect immunoassay solution, delivering unparalleled sensitivity, specificity, precision, and scalability for robust biomarker measurement.

The UK Health Security Agency (UKHSA) has appointed Professor Robin May as Interim Chief Scientific Officer on a one-year appointment.

Molecules exhaled in the breath may help detect blood cancer, according to new research from Queen Mary University of London.

The Serious Hazards of Transfusion (SHOT) scheme has launched the UK’s first blood transfusion information app, co-created with patients, for patients.

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced new measure to modernise and reduce regulations to improve patient access to innovative technologies.

Alpha Laboratories has been acquired by Diploma, a FTSE 100 UK-listed group specialising in value-added technical products and services across life sciences, seals, and controls. Diploma will add value by providing essential products and solutions through a decentralised, customer-orientated approach within each of its end markets.

The Medicines and Healthcare products Regulatory Agency (MHRA) has published its 2024–25 Annual Report and Accounts, and accompanying Impact Report, demonstrating how it has enhanced patient safety across the UK, restored performance to meet regulatory timelines, and successfully enabled access to life-changing medical products.

Linkam Scientific Instruments is showcasing a range of microscopy stages and instrumentation at this year’s Microscopy & Microanalysis conference, including its core stages, new products, and its cryogenic temperature portfolio.

The UKHSA will see its operations move from its current sites in Porton Down, Wiltshire and Colindale in North London to a new National Biosecurity Centre (NBC) in Harlow, Essex, after Government funding for the project was confirmed.

The Government has launched its new Life Sciences Sector Plan as part of its flagship Industrial Strategy, setting out a ten-year mission to harness British science and innovation to deliver long-term economic growth and a stronger, prevention-focused NHS.

The Microbiology Society has expressed concern over the UK Government’s decision to cut funding to the Fleming Fund, a flagship global health programme working to combat antimicrobial resistance (AMR) in low- and middle-income countries (LMICs).

Genomics England will help deliver the 10 Year Health Plan through its digital systems and by generating the evidence to inform how genomics could be embedded into routine care - shaping future approaches to earlier diagnosis, prevention and more personalised treatment.

Waters Corporation and Becton Dickinson (BD) have announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters, creating an innovative life science and diagnostics leader with pioneering technologies.

Bio-Techne has announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology.

Molecular diagnostics group Yourgene Health has launched LightBench Discover, a high-precision 3-in-1 instrument for genomic research laboratories conducting long-read sequencing.

Serious Hazards Of Transfusion (SHOT) has published its new Transfusion Safety Standards, covering various aspects of patient care and staff wellbeing.

The Government has announced its intention to amend the Medical Devices Regulations 2002 for Great Britain to incorporate EU Common Specifications for high-risk in vitro diagnostic (IVD) devices and to repeal regulations on Coronavirus Test Device Approvals (CTDA).

Aiforia Technologies has established a subsidiary in France to strengthen its local presence and to support its growing business in the country.

Artificial intelligence and digital pathology firm PathAI has unveiled the launch of the Precision Pathology Network (PPN), a first-of-its-kind network of digital anatomic pathology laboratories, which aims to platform expands access to latest AI products, unlock real-world data value, and fuel collaborative research with biopharma across a broad network.